EDTA chelating agents

PreclinicalSmall molecule

EDTA chelating agents is one of 68 small molecule programs targeting Diabetic Nephropathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic NephropathyActive, not recruiting

RandomizedRecruiting

Diabetic NephropathyPreclinical

Active, not recruiting

RandomizedPreclinical

Recruiting

Competition

Competitive Landscape

48 competitors in Diabetic Nephropathy

#DrugCompanyPhaseTrials

Aldactone

Pfizer

Approved

6 2

Farxiga

AstraZeneca

Approved

3 3

Zemplar

AbbVie

Approved

1 4

Rocaltrol

Jazz Pharmaceuticals

Approved

1 5

Avapro

Sanofi

Approved

1 6

Lorelco

Sanofi

Approved

1 7

Ozempic

Corlanor

Defitelio

Kerendia

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Randomized1 trial

Chitosan Irrigation in Premolar Root Canal Therapy (Randomized Trial)

Recruiting·EESRA DAĞCI·N/A·NCT07048028·90 enrolled

Diabetic Nephropathy1 trial

Environmental Exposure to Lead and Progressive Renal Insufficiency in Type II Diabetic Nephropathy

Completed·—·N/A·NCT00237952

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for EDTA chelating agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EDTA chelating agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EDTA chelating agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ESRA DAĞCI company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EESRA DAĞCI

EDTA chelating agents

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Randomized1 trial

Diabetic Nephropathy1 trial

References

Drug Info

Quick Facts

Related News